lewis lung carcinoma

Oglufanide (H-Glu-Trp-OH) is a naturally occurring thymic immunomodulator that inhibits vascular endothelial growth factor (VEGF).

PLD1 inhibitor is a compound that targets phospholipase D1 (PLD1). It suppresses PLD activity in A549 cells overexpressing PLD1 with an IC50 of 1.97 µM. This inhibitor also decreases the viability of A549 lung cancer and HCT116 colorectal cancer cells, with IC50 values of 18 and 29 µM, respectively. Furthermore, it impairs proliferation, migration, and invasion of A549 cells and triggers apoptosis. Administered at 10 mg/kg every other day, PLD1 inhibitor diminishes tumor growth, induces intratumoral apoptosis, and lowers levels of Ras, CD47, CD24, and programmed cell death 1 ligand 1 (PD-L1) in a murine Lewis lung carcinoma model.

TAS-103 is a dual inhibitor of DNA topoisomerase I/II, utilized in cancer research.

Anguinomycin A is an antibiotic first isolated from a Streptomyces sp. and analog of leptomycin B that is highly cytotoxic to mouse P388 leukemia cells in vitro (IC50 = 0.1-0.2 ng/ml). It also demonstrates antitumor activity at 62.5 μg/kg/day against Lewis lung carcinoma in mice.

12(S)-HETE is a product of arachidonic acid metabolism through the 12-lipoxygenase pathway. It is primarily found in platelets, leukocytes, and to a lesser extent in smooth muscle cells. It enhances tumor cell adhesion to endothelial cells, fibronectin, and the subendothelial matrix. tetranor-12(S)-HETE is the major β-oxidation product resulting from peroxisomal metabolism of 12(S)-HETE in numerous tissues, and Lewis lung carcinoma cells. No biological function has yet been determined for tetranor-12(S)-HETE. Some data indicate it may play a role in controlling the inflammatory response in injured corneas. In some diseases (e.g., Zellweger's Syndrome) peroxisomal abnormalities result in the inability of cells to metabolize 12(S)-HETE, which may be responsible for symptoms of the disease. The tetranor derivative of 12(S)-HETE is available as a research tool for the elucidation of the metabolic fate of its parent compound.

Carbetimer is a partially imidized copolymer of ethylene & maleic anhydride with average MW approx 1,200 daltons; capable of specific stimulation of immune response. Carbetimer is a low molecular weight polymer derived from ethylene and maleic anhydride with potent antineoplastic activity. Preclinical studies have shown antitumor effects against many tumor cell lines including B 16 melanoma. Its antitumor actions are felt to include both reduction of uridine and cytidine nucleoside triphosphate as well as the diminution of pyrimidine salvage by inhibiting uridine, cytidine, and thymidine kinase. Besides direct antiproliferative effects, Carbetimer could act through immunomodulation, as suggested by the induction of cytotoxic T-cells in mice and the discordant in vitro and in vivo activities against the Lewis lung carcinoma model.

Roxadustat-D5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat (T2515) is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (T2515) (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg/kg. Roxadustat (T2515) reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5/6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......

PD-1/PD-L1-IN-10 is an orally available PD-1/PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity.

Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.

Lipid PPz-2R1 is an ionizable cationic lipid employed in crafting lipid nanoparticles (LNPs) for mRNA delivery both in vitro and in vivo. LNPs with lipid PPz-2R1, encapsulating an mRNA reporter, target the lungs preferentially over the heart, liver, spleen, and kidneys in mice. Additionally, these LNPs, when encapsulating mRNA encoding phosphatase and tensin homolog (PTEN), enhance PTEN protein levels in PTEN-deficient Lewis lung carcinoma (LLC) cells. In an orthotopic murine LLC model, these Lipid PPz-2R1-containing LNPs, carrying PTEN mRNA, reduce tumor growth either when administered alone or alongside an antibody against programmed cell death protein 1 (PD-1).

Roxadustat-D5 (Standard) is a reference standard of Roxadustat-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Roxadustat-d5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg/kg. Roxadustat reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5/6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......

Lucialdehyde B exhibits potent inhibitory activity against herpes simplex virus. It shows cytotoxic effects on Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines.

Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitum